Eli Lilly & Co. (NYSE:LLY), a global leader in pharmaceuticals and biotechnology, continues to strengthen its position in innovative therapeutic areas. In recent weeks, it has made several key moves impacting its strategic development, stock market and regulatory environment.
1. Acquisition of Verve Therapeutics for $1.3 billion
Eli Lilly announced that it has entered into an agreement to acquire Verve Therapeutics, a company specializing in gene editing for cardiovascular disease. The transaction value is up to $1.3 billion, with $1 billion to be paid in cash and an additional $300 million contingent on the achievement of clinical milestones.
The acquisition expands Eli Lilly & Co (NYSE:LLY)’s research and development portfolio to include technologies targeting single-gene applications in its Verve-102 program, which is focused on inhibiting the PCSK9 protein. Analysts, including Bernstein Research, evaluated the move as a good strategic move and also reiterated an investment recommendation of “Outperform” with an average target price with a high estimate of $1,100 per share.
2. Current LLY Share Price Trend
Eli Lilly’s share price is currently trading around $785.03 (as of June 19, 2025), representing a year-over-year decline of approximately -0.8%. The daily trading range was $779.75 to $793.85. The stock is roughly 16% below its all-time high.
Eli Lilly & Co (NYSE:LLY) also pays a regular quarterly dividend. The dividend yield is currently $1.50 per share. The company’s dividend per share was approved by the company’s board of directors at 0.76% per share. Further, analysts at Zacks.com have set an average target price of $983.13 per share for the short to medium term investment horizon.
Graph Source : www.zacks.com
3. Alzheimer’s drug Kisunla
The company also faces regulatory constraints in the European market, specifically in the UK, where NICE has recommended against reimbursement of Kisunla (donanemab) for patients with mild cognitive decline. Eli Lilly & Co (NYSE:LLY) filed a formal appeal based on successful research and testing from clinical trials with the support of the expert community. Despite this move, use of the product in the United States and other regions remains speculative.
4. Legal Protections Against Unauthorized Copies of GLP-1 Drugs
The Company has also taken legal action against several companies that illegally manufacture and distribute unapproved versions of GLP-1 agonist-based drugs. Among the companies sued are Fella Health and Willow Health. Lilly’s move underscores the importance of quality control and drug safety.
Conclusion
Eli Lilly continues its dynamic growth through strategic acquisitions and an innovative approach to pharmaceutical development. Despite regulatory challenges in the neurodegenerative disease space, it remains an attractive entity for long-term investors. Its emphasis on obesity, gene therapy and intellectual property protection continues to define its market trajectory.
